Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - atenolol, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; propyl hydroxybenzoate; saccharin sodium; purified water; citric acid monohydrate; sorbitol solution (70 per cent) (non-crystallising); sodium citrate dihydrate; methyl hydroxybenzoate; flavour - all grades of hypertension including hypertension of renal origin.,frequent disabling angina without evidence of cardiac failure,cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those with acute myocardial infarction),myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - riluzole, quantity: 0.5 g - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); aluminium magnesium silicate; xanthan gum; saccharin sodium; sodium lauryl sulfate; ceteareth-25; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als).

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - diazepam, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: ethanol; propylene glycol; glycerol; citric acid; sodium citrate dihydrate; purified water; flavour - indications as at 30 september 2003: diazepam is indicated in the management of anxiety disorders and for the short term relief of the symptoms of anxiety. diazepam is a useful adjunct for the relief of reflux muscle spasm due to local trauma (injury, inflammation) to muscles, bones and joints. it is also indicated in the management of cerebral spasiticity due to upper motor neuron lesions such as cerebral palsy and paraplegia, and spasticity in athetosis and stiff man syndrome. in acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion laboratories pty ltd t/a perrigo australia - chloral hydrate, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: sucrose; citric acid; sodium citrate dihydrate; saccharin sodium; glycerol; methyl hydroxybenzoate; ethanol; propylene glycol; purified water; flavour - indications as at 19 september 2003: chloral hydrate mixture is indicated pre-operatively to produce sedation. it is also indicated for short term (not more than 2 weeks) use as a hypnotic to assist in sleep disorders.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

al multaqa drugs and pharmaceutical spain - 10ml x 20 bottle - liquid - comination - nutrition , blood-vitamins

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

10ml x 20 bottle -

Philippines - English - FDA (Food And Drug Administration)

methyl salicylate , menthol , eucalyptus oil - liniment oil classification: household remedy (hr) - 27 mg/ 25 mg/ 6 mg per 100 ml dosage

Uganda - English - National Drug Authority

f. hoffmann la-roche - rituximab - parenteral ordinary infusion vials/bottles - 100mg/10ml

Uganda - English - National Drug Authority

sandoz gmbh, kundl - 5-fluorouracil - parenteral ordinary infusion vials/bottles - 500 mg/10 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ezetimibe, quantity: 10 mg - tablet, uncoated - excipient ingredients: crospovidone; povidone; lactose monohydrate; sodium lauryl sulfate; stearic acid; colloidal anhydrous silica - adults (greater than or equal to 18 years),primary hypercholesterolaemia,ezetimibe gh administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,homozygous familial hypercholesterolaemia (hofh),ezetimibe gh, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).,homozygous sitosterolaemia (phytosterolaemia) ezetimibe gh is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia. prevention of cardiovascular disease,ezetimibe gh is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see section 5.1 pharmacodynamic properties ? clinical trials).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post-menarche),heterozygous familial hypercholesterolaemia (hefh),ezetimibe gh co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate:,patients not appropriately controlled with a statin or ezetimibe alone.;,patients already treated with a statin and ezetimibe.,homozygous familial hypercholesterolaemia (hofh),ezetimibe gh co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (eg. ldl apheresis).